Adamo S, Siliprandi N, Dl Lisa F, Carrara M, Azzurro M, Sartori G, Vita G, Ghidini O. Effect of L-carnitine on ethanol and acetate plasma levels after oral administration of ethanol in humans. Alcohol Clin Exp Res 1988;12:653-4.
Arenas J, Huertas R, Campos Y, Diaz AE, Villalon JM, Vilas E. Effects of L-carnitine on the pyruvate dehydrogenase complex and carnitine palmitoyl transferase activities in muscle of endurance athletes. FEBS Lett 1994;341:91-3.
Breningstall GN. Carnitine deficiency syndromes. Pediatr Neurol 1990;6:75-81.
Brevetti G, di Lisa F, Perna S, Menabo R, Barbato R, Martone VD, Siliprandi N. Carnitine-related alterations in patients with intermittent claudication: indication for a focused carnitine therapy. Circulation 1996;93:1685-9.
Campos Y, Huertas R, Lorenzo G, Bautista J, Gutierrez E, Aparicio M, Alesso L, Arenas J. Plasma carnitine insufficiency and effectiveness of L-carnitine therapy in patients with mitochondrial myopathy. Muscle Nerve 1993;16:150-3.
Corbucci GG, Lettieri B. Cardiogenic shock and L-carnitine: clinical data and therapeutic perspectives. Int J Clin Pharmacol Res 1991;11:283-93.
Davini P, Bigalli A, Lamanna F, Boem A. Controlled study on Lcarnitine therapeutic efficacy in post-infarction. Drugs Exp Clin Res 1992;18:355-65.
de los Reyes B, Navarro JA, Perez-Garcia R, Liras A, Campos Y, Bornstein B, Arenas J. Effects of L-carnitine on erythrocyte acyl-CoA, free CoA, and glycerophospholipid acyltransferase in uremia. Am J Clin Nutr 1998;67:386-90.
Digiesi V, Cantini F, Bisi G, Guarino G, Brodbeck B. L-carnitine adjuvant therapy in essential hypertension. Clin Ter 1994;144:391-5.
Fujiwara M, Nakano T, Tamoto S, Yamada Y, Fukai M, Takada K, Ashida H, Shimada T, Ishihara T, Seki I. [Effect of L-carnitine in patients with ischemic heart disease]. J Cardiol 1991;21:493-504.
Ghidini O, Azzurro M, Vita G, Sartori G. Evaluation of the therapeutic efficacy of L-carnitine in congestive heart failure [published erratum appears in Int J Clin Pharmacol Ther Toxicol 1989 Aug;27(8):418]. Int J Clin Pharmacol Ther Toxicol
1988;26:217-20.
Giamberardino MA, Dragani L, Valente R, Di Lisa F, Saggini R, Vecchiet L. Effects of prolonged L-carnitine administration on delayed muscle pain and CK release after eccentric effort. Int J Sports Med 1996;17:320-4.
Goa KL, Brogden RN. l-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism. Drugs 1987;34:1-24.
Kendler BS. Carnitine: an overview of its role in preventive medicine. Prev Med 1986;15:373-90.
Kendler BS. Recent nutritional approaches to the prevention and therapy of cardiovascular disease. Prog Cardiovasc Nurs 1997;12:3-23.
Matsui S, Sugita T, Matoba M, Murakami E, Takekoshi N, Shinka T, Matsumoto I. Urinary carnitine excretion in patients with heart failure. Clin Cardiol 1994;17:301-5.
Mondillo S, Faglia S, D'Aprile N, Mangiacotti L, Campolo MA, Agricola E, Palazzuoli V. [Therapy of arrhythmia induced by myocardial ischemia. Association of L- carnitine, propafenone and mexiletine]. Clin Ter 1995;146:769-74.
Palazzuoli V, Mondillo S, Faglia S, D'Aprile N, Camporeale A, Gennari C. [The evaluation of the antiarrhythmic activity of Lcarnitine and propafenone in ischemic cardiopathy]. Clin Ter 1993;142:155-9.
Pepine CJ. The therapeutic potential of carnitine in cardiovascular disorders. Clin Ther 1991;13:2-21; discussion 1. Pugliese D, Sabba C, Ettorre G, Berardi E, Antonica G, Godi L, Palasciano G, Lee SS, Albano O. Acute systemic and splanchnic haemodynamic effects of L-carnitine in patients with cirrhosis. Drugs
Exp Clin Res 1992;18:147-53.
Regitz V, Shug AL, Fleck E. Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. Am J Cardiol 1990;65:755-60.
Scholte HR, Luyt-Houwen IE, Vaandrager-Verduin MH. The role of the carnitine system in myocardial fatty acid oxidation: carnitine deficiency, failing mitochondria and cardiomyopathy. Basic Res Cardiol 1987;82:63-73.
Scholte HR, Rodrigues Pereira R, Busch HF, Jennekens FG, Luyt-Houwen IE, Vaandrager-Verduin MH. Carnitine deficiency, mitochondrial dysfunction and the heart. Identical defect of oxidative phosphorylation in muscle mitochondria in cardiomyopathy due to carnitine loss and in Duchenne muscular dystrophy. Wien Klin Wochenschr 1989;101:12-7.
Siliprandi N, Sartorelli L, Ciman M, Di Lisa F. Carnitine: metabolism and clinical chemistry. Clin Chim Acta 1989;183:3-11.
van Es A, Henny FC, Kooistra MP, Lobatto S, Scholte HR. Amelioration of cardiac function by L-carnitine administration in patients on haemodialysis. Contrib Nephrol 1992;98:28-35.
Vecchiet L, Di Lisa F, Pieralisi G, Ripari P, Menabo R, Giamberardino MA, Siliprandi N. Influence of L-carnitine administration on maximal physical exercise [see comments]. Eur J Appl Physiol 1990;61:486-90. |
